Maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization

Analysis from a population cohort in Israel found that a third booster dose of the BNT162b2 mRNA vaccine in mothers before or during pregnancy was associated with greater protection against COVID-19 hospitalization in their infants compared to two doses. Infants are at a higher risk of Coronavirus Disease 2019 (COVID-19)-related hospitalizations compared to older children. In this study, we investigated the effect of the recommended third maternal dose of BNT162b2 COVID-19 vaccine during pregnancy on rates of infant COVID-19-related hospitalizations. We conducted a nationwide cohort study of all live-born infants delivered in Israel between 24 August 2021 and 15 March 2022 to estimate the effectiveness of the third booster dose versus the second dose against infant COVID-19-related hospitalizations. Data were analyzed for the overall study period, and the Delta and Omicron periods were analyzed separately. Cox proportional hazard regression models estimated hazard ratios and 95% confidence intervals (CIs) for infant hospitalizations according to maternal vaccination status at delivery. Among 48,868 live-born infants included in the analysis, rates of COVID-19 hospitalization were 0.4%, 0.6% and 0.7% in the third-dose, second-dose and unvaccinated groups, respectively. Compared to the second dose, the third dose was associated with reduced infant hospitalization with estimated effectiveness of 53% (95% CI: 36-65%). Greater protection was associated with a shorter interval between vaccination and delivery. A third maternal dose during pregnancy reduced the risk of infant hospitalization for COVID-19 during the first 4 months of life, supporting clinical and public health guidance for maternal booster vaccination to prevent infant COVID-19 hospitalization.

Automated summary

An analysis in Israel found that a third booster dose of the BNT162b2 mRNA vaccine given to mothers before or during pregnancy provides greater protection against COVID-19 hospitalization in infants compared to two doses. This nationwide cohort study investigated the effectiveness of the third maternal dose versus the second dose in preventing infant COVID-19-related hospitalizations. The third dose was associated with a 53% reduced risk of infant hospitalization compared to the second dose.